Last reviewed 2026-04-23 · How we verify

VC005

VC005 is a small molecule that targets the SGLT2 receptor.

VC005 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Mechanism of action

By inhibiting SGLT2, VC005 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.

Approved indications

• Type 2 diabetes

Common side effects

• Nausea
• Diarrhea
• Vomiting

Key clinical trials

• Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis (PHASE1)
• Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo (PHASE2)
• Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. (PHASE3)
• The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers (PHASE1)
• Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis (PHASE2)
• Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis (PHASE3)
• Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis (PHASE1)
• Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.